FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:937-939 March 3, 2005 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The PEACE Trial Investigators PubMed Citation

To the Editor: The results of the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial¹ (Nov. 11 issue)¹ are probably the product of an underpowered trial. Only 8290 of a planned 14,100 patients were enrolled, and the primary outcome was changed to include revascularization — an outcome that depends on practice styles and that is therefore potentially insensitive to treatment. Two other trials, the Heart Outcomes Prevention Evaluation Study (HOPE)² and the European Trial of Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA),³ showed significant reductions in the spontaneous and major vascular outcomes. The . . . [Full Text of this Article]

This article has been cited by other articles:

• Fox, K. (2008). Benefits of perindopril all along the cardiovascular continuum: the level of evidence. Eur Heart J Suppl 10: G4-G12 [Abstract] [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Donnelly, R., Manning, G. (2007). Review: Angiotensin-converting enzyme inhibitors and coronary heart disease prevention. Journal of Renin-Angiotensin-Aldosterone System 8: 13-22 [Abstract]  
• Fox, K., Ferrari, R., Yusuf, S., Borer, J. S. (2006). Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?. Eur Heart J 27: 2154-2157 [Abstract] [Full Text]  
• Strauss, M. H., Hall, A. S. (2006). Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox. Circulation 114: 838-854 [Full Text]  
• Al-Mallah, M. H., Tleyjeh, I. M., Abdel-Latif, A. A., Weaver, W. D. (2006). Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 47: 1576-1583 [Abstract] [Full Text]  
• Danchin, N., Cucherat, M., Thuillez, C., Durand, E., Kadri, Z., Steg, P. G. (2006). Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials.. Arch Intern Med 166: 787-796 [Abstract] [Full Text]  
• Koh, K. K., Han, S. H., Quon, M. J. (2005). Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions. J Am Coll Cardiol 46: 1978-1985 [Abstract] [Full Text]  
• Demers, C., McMurray, J. J. V., Swedberg, K., Pfeffer, M. A., Granger, C. B., Olofsson, B., McKelvie, R. S., Ostergren, J., Michelson, E. L., Johansson, P. A., Wang, D., Yusuf, S., for the CHARM Investigators, (2005). Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. JAMA 294: 1794-1798 [Abstract] [Full Text]  
• Gabriel Steg, P., Himbert, D. (2005). Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J Suppl 7: H7-H15 [Abstract] [Full Text]